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1. Introduction
The rapid evolution of medical therapy, percutaneous coronary interventional techniques and
cardiac surgery along with the changing patient profile over the last few decades has required
the clinician to make increasingly complex decisions. This has led to significant variations in
practices that may be discordant with evidence based clinical practice guidelines. Such
variations have an unclear clinical impact. There is hope that with growing efforts to apply
multidisciplinary care to the management of complex coronary artery disease (CAD),that we
will arrive at more consistent and balanced decisions.
In this chapter, we will explore (1) The history of angiography and angioplasty, (2) the current
clinical dilemma (3) the evidence supporting the use of cardiac surgery to improve survival
above medical therapy alone, (4) the role of percutaneous approach versus surgery in different
populations, (5) the impact of changing technologies/techniques in revascularization, (6) the
current discordance between guidelines and clinical practice, and (7) the potential role of a
multidisciplinary Heart Team to create a more unified, balanced approach to the treatment of
complex CAD.
2. The origins of the age of percutaneous revascularization
2.1. Cardiac catheterization
One of the earliest descriptions of cardiac catheterizations was done by Steven Hales, an
English chemist, botanist and animal physiologist who cannulated the carotid artery and the
jugular vein to access the left and right-sided chambers of the heart respectively in the 17th
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century [1]. It was through some of this initial work, that he was able to make the first
measurements of blood pressure, describe systole and diastole, characterize the volumes of
the heart through wax cast work and correctly describe the function of the aortic and mitral
valve [1]. Interestingly, the first human cardiac catheterization was by a Urologist by the name
of Werner Forssmann [2]. He performed right heart catheterization on himself in 1929 by
advancing a cannula through the left antecubital vein via cut-down access into the right atrium
[2].
2.2. Selective coronary angiography and angioplasty
The credit of the first true selective coronary angiogram and much of the initial correlations
between angina pectoris and coronary anatomy has to be granted to Mason Sones, a Pediatric
Cardiologist, who at the time of discovery was working out of the Cleveland clinic [3-5]. In
1958, whilst performing non-selective aortogram on a patient, Sones inadvertently engaged
the right coronary artery [2].
The original technique of angioplasty was born out earlier work by a Vascular Radiologist by
the name of Charles Theodore Dotter [6]. Andreas Gruentzig, now known as the father of
modern day coronary angioplasty, learned the Dotter technique from a German Radiologist
Eberard Zeitler while doing a clinical fellowship in the Radiology Department of Aggertalclinic
in Engelskirchen, Germany [6]. He had adopted the Dotter concept of using the balloon
approach for angioplasty [6]. After experimenting with a number of materials performed the
first procedure in 1977 in a man with stenosis of his left anterior descending artery (LAD) using
a polyvinyl chloride balloon mounted onto the Dotter catheter [6].
3. The current dilemma
The treatment of coronary artery disease can be simplified into three major therapeutic
approaches: medical therapy alone, percutaneous coronary intervention (PCI), and coronary
artery bypass grafting (CABG). However, deciding on which approach is optimal for the
individual patient is sometimes far from simple. This decision requires not only an in depth
understanding of the evidence but also the applicability of this evidence to the individual
patient considering the anatomic characteristics of the disease, the clinical context, the patient’s
preferences, social circumstances, and available resources [ie. local expertise and access to PCI
and/or CABG]. Furthermore, because there has been evolution of all of these three approaches,
interpretation of the evidence has become quite complex. Comparison of different modes of
therapy (eg CABG versus medical therapy or CABG to balloon angioplasty) in the past may
not be as relevant in the current clinical milieu.
3.1. Advances in medical therapy
Medical therapy has made remarkable advances from a time when patients may have been
treated with nitrates alone to contemporary use of a combination of antiplatelets, lipid
lowering therapy (statins), beta-blockers (BB) and Angiotensin Converting Enzyme- inhibitors
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(ACEI)/Angiotensin Receptor Blocker (ARB). This combined therapy addresses not only
patient symptoms but also modifies the disease process such that prognosis is vastly improved
[7]. The growth in our understanding the impact of lifestyle modification has also played a
central role in how we manage patients with CAD [8].
3.2. Changing clinical patient profile
Due to advances in medical therapy, patients that are now considered for revascularization
are also older and have accrued more co-morbidities [9]. These co-morbidities render the
interpretation of relevant symptoms more difficult. For example, in a diabetic patient with
chronic obstructive lung disease (COPD), it may be difficult to distinguish between dyspnea
as an anginal equivalent versus that caused by the underlying pulmonary pathology. The
severity of the patients’ COPD may also complicate the eligibility for CABG as a mode of
revascularization [10, 11]. In fact, in a recent clinical trial comparing CABG versus PCI in
complex CAD, significant burden of co-morbidities was the most common reason that patients
were felt not to be suitable for CABG and hence entered into the PCI registry [9].
3.3. Advances in angioplasty
Angioplasty has significantly evolved over the last several decades with respect to four
principle areas. First, operator training has advanced from informal training courses to 1-2
year formal clinical fellowships [12, 13]. Second, the equipment to perform PCI has signifi‐
cantly improved from plain old balloon angioplasty (POBA) to second-generation drug-
eluting stents (DES) and supporting devices to improve PCI outcomes (filter wires,
thrombectomy in ST elevation acute coronary syndrome (STEACS), and rotational arthrecto‐
my) [14, 15]. Third, vascular access has evolved from brachial cut-downs with large caliber
sheaths (7-8 FR) to increasingly common radial access with smaller caliber sheaths (5 and 6
FR) [5, 15-18]. Finally, concomitant medications have become more sophisticated, from Aspirin
(ASA) alone to combination antiplatelets resulting in reduced stent thrombosis [19]. Restenosis
has remained in the forefront of limitation to PCI[20]. However, the challenges with restenosis
have been significantly reduced with advancement in DES technology [21-23]. Concerns with
the thrombosis rates in the setting of discontinuation of dual antiplatelet therapy (DAPT) after
DES have been addressed by second-generation DES, which have dramatically reduced this
clinical problem [24]. These advances have been paralleled by an increasing use in complex
coronary artery disease including left main (LM) disease[25].
3.4. Advances in surgical techniques
From the standpoint of CABG, we have over the years learned the benefits of arterial grafting
with the internal mammary artery (IMA) in improving survival [26]. A high long-term patency
rate of left internal mammary artery (LIMA) after revascularization of the LAD is well
established and is estimated at 88 percent at 10 to 15 years [26]. More recently, to circumvent
particular risks associated with sternotomy, there has been some investigation of revasculari‐
zation of the LAD with the LIMA using a minimally invasive direct coronary artery bypass
(MIDCAB) technique [26]. In the setting of multivessel disease (MVD), there has been some
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discussion of a hybrid approach with MIDCAB for the LAD and PCI of the other vessels.
However, the evidence supporting this approach is still limited; the most recent European
Society of Cardiology (ESC) Guidelines give a Class IIb recommendation to this approach (Level
of Evidence B) for those “patients with conditions likely to prevent healing after sternotomy” [26]. This
approach does have significant promise and further research is required before it is adopted
on a population level.
3.5. Evidence of survival benefit for revascularization in stable ischemic heart disease
(SIHD)
The current framework for patient selection in treatment strategy for MVD is largely shaped
by early studies comparing medical therapy and CABG. This body of evidence has been best
synthesized by a meta-analysis performed by Yusuf et al in the Lancet in 1994 [27]. This meta-
analysis was an individual patient data analysis of 2549 patients derived from three large
randomized controlled trials, the Coronary Artery Surgery Study (CASS), Veterans Adminis‐
tration (VA) study and the European Coronary Surgery Study (ECSS) as well as four other
smaller randomized studies [27]. The population studied consisted of patients with stable
symptomatic coronary artery disease of a wide spectrum of severity [27]. However, only 10
percent were single vessel disease (1VD); the remainder consisted of MVD with 59.4% affecting
the proximal LAD [27].
Figure 1. Survival curve for medical therapy versus coronary artery bypass grafting (CABG). Reproduced with permis‐
sion from Yusuf S. et al. Lancet 1994. 344;8922:563-568
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There was an overall statistically significant survival benefit with an absolute risk reduction
(ARR) 5.6% at 5 years, 5.9% at 7 years and 4.1% at 10 years [Figure 1] [27]. This was likely
an overall underestimate of the total treatment effect as there was a 36.4% cross over from
the medical group to CABG over that time period whereas 93.7% of those assigned to the
surgical group underwent CABG [27]. Subgroup analysis revealed that benefit was largely
in those that had three-vessel disease (3VD) and those with involvement of the proximal LAD with
each of those groups demonstrating a 42% relative risk reduction (RRR) in mortality [27]. In
contrast, revascularization in two-vessel disease (2VD) in the absence of involvement of the
proximal LAD did not result in a significant mortality benefit [27]. Randomized data is fairly
consistent with that of registry data, demonstrating survival benefit for revascularization
over medical therapy in those with 3VD; its support for benefit in those with 2VD even in
those with proximal left anterior descending (LAD) involvement was non-significant [28].
The latter may be related to improvements in medical therapy.
4. Changing landscape in the treatment of CAD
Many of the earlier studies comparing surgical revascularization with medical therapy was
during a period in cardiology where the BB and nitrates were the mainstay of medical therapy.
Although antiplatelets were available, these were only taken by approximately 20% of the
patients at the time [27]. It may hence be important to interpret these results in the context of
current medical practice, which include contemporary treatments (standard secondary
prevention with antiplatelets, statin therapy, BB and ACEi) that have all made further
advancements in the survival and prognosis of patients with CAD [7].
ASA for secondary prevention has an estimated RRR of 18 percent in total serious vascular
events (including stroke and major coronary event) with an annual ARR of 1.5 percent; the
decrease in major coronary event (non-fatal myocardial infarction (MI) and cardiovascular
death) is estimated at annual ARR of 1.0 percent [29]. As an adjunctive antiplatelet clopidogrel
has further reduced death from cardiovascular causes, non-fatal MI and stroke in patients with
Non ST elevation acute coronary syndromes (NSTEACS) with an ARR of 2.1 percent [30]. Most
recently, newer agents such as prasugrel and ticagralor have both shown benefit compared to
clopidogrel in patients with acute coronary syndromes (ACS). Prasugrel compared with
clopidogrel in PCI treated ACS has demonstrated an ARR of 2.2 percent with regards to death
from cardiovascular causes, nonfatal MI or non-fatal stroke over the 6-15 month follow up
period [31]. Ticagralor has shown similar reduction in the same composite endpoint in patients
with ACS over clopidogrel with an ARR of 1.9 percent [32]. In addition, ticagralor also showed
an overall reduction in all cause mortality with an ARR of 1.4 percent [32].
BB’s have a longstanding history in the management of CAD [7]. Although BB’s can be used
in patients post-MI with a normal ejection fraction (EF), the evidence for this is not as strong
as that for those with significant Left Ventricular (LV) dysfunction [8]. It was previously shown
that Carvedilol compared with placebo in patients with chronic heart failure (HF) and severe
LV dysfunction (average EF 22-23 percent) reduces all cause mortality with an ARR of 4.6
percent [33].
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The introduction of 3-hydroxyl-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase
inhibitors otherwise known as the “statins,” has significantly improved the care of patients
with coronary artery disease [34, 35]. Simvastatin 40mg orally daily compared to placebo in
patients with known vascular disease was shown in the Heart Protection Study (HPS) to reduce
all cause mortality with an ARR of 1.8 percent over a five year period [34]. This was paralleled
with a reduction of coronary death with an ARR 1.2% [34].
ACEi’s have also been established to have a significant benefit towards long-term cardiovas‐
cular outcomes. It was shown in the Heart Outcomes Prevention Evaluation Study that in high-
risk patients (vascular disease or diabetes plus one other risk factor) Ramipril compared with
Placebo provides a relative risk reduction in myocardial infarction, stroke and death from
cardiovascular causes of 21 percent and ARR of 3.8 percent [36] over the mean follow up period
of 5 years. There was also a reduction in all cause death with an ARR of 1.8 percent [36].
Concurrently, there was the advent and evolution of percutaneous approaches to revascula‐
rization. The first generation of angioplasty that truly adopted popular practice involved serial
balloon inflations at the site of stenoses restore normal flow dynamics down the conducting
epicardial vessels [6]. This approach, although promising was limited by a high rate of
restenoses as a result of localized vascular recoil and epithelial hyperplasia [20, 37]. The bare
metal stents (BMS) were created as a scaffolding technique that limited the degree of recoil but
still faced significant re-stenosis rates due to mediated by injury to the medial layer, increased
inflammation resulting from stent strut penetration into the lipid core and ultimately neoin‐
timal growth [38].
Pacitaxel and Sirolimus DES were developed in the next phase to overcome the challenge of
restenosis requiring repeat intervention [20]. Although there was no difference in mortality or
rates of myocardial infarction seen with DES compared with BMS, there were considerable
reductions in restenosis rates with an estimated RRR of 0.44 [21, 22, 39-41].
Early enthusiasm for the use of drug eluting stents was curbed by a significantly higher rate
of stent thrombosis, particularly in the face of an initially shorter duration (6 months) of dual
antiplatelet therapy (DAPT) [22, 42, 43]. Currently the American College of Cardiology/
American Heart Association (ACC/AHA) recommends at least 12 months of DAPT in patients
receiving DES for non-ACS indication and 12 months of DAPT for ACS indication regardless
of the stent type (BMS or DES) (Class I recommendation, Level B evidence) [14].
The most recent development in stent technology has been the introduction of second-
generation (everolimus and zotarolimus) drug eluting stents. A large Swedish registry
observational study containing 94, 384 patients demonstrated the advantage of the second-
generation stents over its predecessors (first generation DES and BMS) both in terms of
restenosis and definite stent thrombosis [44]. The second generation DES in this study was shown
to have lower risk of restenosis compared with both BMS and the first generation DES with
Hazard Ratios (HR) of [0.29, 95% confidence interval (CI) 0.25-0.33] and [0.62, CI: 0.53
-0.72] respectively [44]. The Cobalt Chromium Everolimus eluting stents (CoCr EES) have
shown the most promise in reducing stent thrombosis. In a recent network meta-analysis of
50844 patients, the CoCr EES was shown to have a lower rate of 1 year definite stent thrombosis
compared to both paclitaxel DES and sirolimus DES with odds ratio (OR) of [0.41 95% CI
0.24-0.70] and [0.28 95% CI 0.16-0.48] respectively [24]. The CoCr EES also had a lower rate of
definite stent thrombosis compared with BMS at 1 year and 2 years with an odds ratio [OR] of
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[0.23 95% CI 0.13-0.41) and [0.35, 95% CI 0.17-0.69] respectively [24]. Finally, compared to even
the zotarolimus second generation DES, the CoCr EES still demonstrated a robust reduction
in stent thrombosis with an OR [0.21, 95% CI 0.17-0.69] at one year [24].
5. PCI versus CABG in SIHD
There have been numerous randomized studies comparing PCI with surgical revasculariza‐
tion in MVD. A recent systematic review including 10 major trials over and the individual data
from over 7800 patients found similar mortality in patients treated with CABG (15%) compared
to patients treated with angioplasty (16%) over median survival of 5.9 years (p=0.12) [45]. There
was, however a significantly lower rate of death or repeat revascularization in those treated
with CABG (9.9%) compared with those treated with PCI (24.5%) [45]. This suggests that in
fact the major benefit seen in CABG over PCI in this comparison is a lower need for repeat
revascularization and is paralleled by a lower incidence of angina in the CABG group (14%)
compared to the PCI group (26%) at one year (p<0.0001) [45]. The major caveat to this data is
that stenting (which is known to reduce restenosis rates) only represented 37 percent of the
total angioplasty group [45].
Subgroup analysis revealed that patients with diabetes have overall better survival when treated
with surgical revascularization than when treated with angioplasty with an ARR of 7.7% over
5 years [45]. More definitive data supporting the use of CABG in patients with diabetes will
be presented in Section 6.2. Interestingly, there was also a graded age interaction that was
significant (p=0.002) [45]. For patients younger than 55 years of age, mortality was lower with
PCI (8%) than CABG (10%). In patients between ages 55-64, PCI and CABG had similar
mortality rates at 15 and 14 percent respectively [45]. And for patients older than 65 years of
age, CABG had a lower overall mortality (20%) compared with PCI (24%) [45]. Prior to this
study, this interaction had not been previously reported and we can only speculate whether
the effect is a true function of age.
Other subgroups did not prove to contribute any significant interaction to the overall treatment
effect [45]. Six of the trials included had POBA as the main mode of PCI whereas four trials
used BMS; neither of these groups had significantly different survival rates when compared
with surgery [45]. There was no overall interaction contributed by the presence/absence of
proximal LAD disease, 3VD, abnormal LV function, previous MI or unstable symptoms [45].
6. Factors favoring surgery as the mode of revascularization
6.1. LV dysfunction
LV function has never been shown to have a significant interaction with mode of revasculari‐
zation (PCI versus CABG) with regard to survival. In fact, the majority of studies comparing
PCI with CABG enrolled a low percentage of patients with abnormal LV function (20 percent
or less) [45]. However, it has been considered an important variable that favors revasculariza‐
tion with surgery due to historical data showing that patients with significant LV dysfunction
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have improved survival with CABG compared to medical therapy. An initial signal for
preferential benefit of revascularization in patients with mild to moderate LV dysfunction (LV
EF of 35-49%) was seen in subgroup analyses of the CASS randomized study and the VA study
[46, 47]. This was further supported by a meta-analysis demonstrating a significantly longer
survival time in 10-year follow up with surgical revascularization over medical therapy in
patients with LV dysfunction [10.6 months] compared with those with normal LV function
[2.3 months] [27]. These studies however did not address whether a similar effect would be
seen in severe LV dysfunction.
The Surgical Treatment for Ischemic Heart Failure (STITCH) trial published recently in 2011,
designed to address this question in a randomized comparison of medical therapy versus
surgical revascularization in patients with an EF of 35 percent or less [48]. There was a non-
statistically significant trend (p=0.12) towards decreased all-cause mortality in the surgical
group with an relative reduction of 24% and an ARR of 5 percent over the six year follow up
period [48]. The lack of statistical significance, in the context of intention to treat analysis, may
be related to the disproportionate crossover rate with 17 percent of the patients assigned to
medical therapy ultimately receiving coronary bypass surgery [48]. Nevertheless, there was
still a significant relative reduction of death from cardiovascular causes of 19 percent (p=0.05)
and a significant relative reduction in death from any cause and hospitalization from cardio‐
vascular causes of 26 percent (p<0.001)[48].
It is unclear why surgical revascularization confers clear benefit in mild to moderate LV
dysfunction, and only modest benefit severe LV dysfunction, but there are possible explana‐
tions. Medical therapy has advanced tremendously since the initial comparisons between
medical therapy and surgery, which may decrease the relative mortality benefit between the
two treatments during this more contemporary comparison. One could also hypothesize that
the beneficial effect of revascularization plateaus at the extremes of LV dysfunction due to
irreversible remodelling and/or the progressive increase in associated procedural risk.
There is currently limited data in how revascularization with PCI would affect prognosis in
the setting of LV dysfunction[14]. As a result, the most recent ACC/AHA guidelines still
recommend CABG for patients with LV EF 35-50 percent with a IIa recommendation (Grade B
evidence) and a IIb recommendation (Grade B evidence) for those with a LV EF of less than 35
percent [49]. And currently, the ACC/AHA guidelines state that there is insufficient data to make
a recommendation for revascularization with PCI in patients with LV dysfunction [49]. In
practice however, if a patient does require revascularization but is not a surgical candidate,
that natural decision is that if percutaneous intervention is feasible, that option should be
entertained.
6.2. Diabetes favoring surgical revascularization
The Bypass Angioplasty Revascularization Investigation (BARI) was one of the first major
landmark studies comparing angioplasty versus coronary bypass in patients with both stable
anginal symptoms and unstable angina with MVD. Although there was no significant
difference between the two treatments in the overall survival, patients with diabetes tended
to have a significantly lower mortality rate with CABG (19.4%) compared with angioplasty
(34.5%) with an ARR of 15.1% [50]. This finding was further confirmed with a meta-analysis
comparing angioplasty with CABG in MVD, albeit with a smaller ARR of 7.7% [45]. In contrast,
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in non-diabetics there was no overall benefit of surgery over angioplasty[45]. This relationship
was corroborated by significant interaction found for the diabetic subgroup (p=0.014) [45]. The
interaction was robust and was present even after excluding the data contributed by BARI and
when adjusted for various clinical parameters (age, sex, smoking, hypertension, history of MI,
heart failure and 3VD) [45].
One hypothesis that may explain why diabetics may have a better outcome with surgery than
angioplasty is that restenosis may be more aggressive in this group of patients [20]. It has been
well established that one major drawback of percutaneous coronary intervention is the need for
repeat revascularization due to restenosis [20]. While restenosis itself may not incur an in‐
creased risk of mortality, the repeat exposure to the inherent risk of intervention may be additive.
The need for repeat revascularization was certainly more striking in the earlier trials where POBA
was used (54 percent within 5 years for the BARI trial) [50]. There has been considerable
improvement to both the techniques and technology of PCI first with the development of BMS
and now DES which are intended to reduced restenosis rates have been integrated into common
practice. However, even in more contemporary trials such as Synergy between PCI with Taxus and
Cardiac Surgery (SYNTAX), DES conferred a 13.5% need for revascularization compared with
5.9% in patients treated with CABG over a one-year period [51].
BARI 2D is a contemporary trial evaluating revascularization (both PCI and CABG) with
intensive medical therapy for SIHD in diabetic patients. No significant difference emerged
overall between the two groups in terms of overall mortality, cardiac death or myocardial
infarction over the 5-year follow up period [52]. The mode of revascularization was at the
discretion of the treating physician and the burden of disease tended to be higher in the CABG
group than the PCI group with a mean number of lesions being 5.6 versus 4.3 respectively [52].
Although not specifically designed to compare PCI and CABG as a mode of revascularization,
it is still noteworthy that there was a significant difference in death and MI for those revascu‐
larized with CABG compared to medical therapy (21.1% versus 29.2% p=0.010); the same
comparison in the PCI stratum revealed no difference [52].
To date, the trial most relevant in determining whether the difference between PCI and CABG
for revascularizing SIHD in diabetic patients in a randomized fashion is the FREEDOM trial
[53]. There are 1900 diabetic patients with multivessel disease (defined by >70% stenosis in 2
or more epicardial vessels supplying different vascular territories) that were randomized to
CABG versus PCI with DES (Paclitaxel or Sirolimus eluting stent at the discretion of treating
physician) with a background of guideline supported optimal medical therapy. The primary
endpoint is a composite of all-cause mortality, non-fatal MI or stroke over the mean follow up
period of 4.37 years [53]. This consists of a high-risk population with 83% having 3-vessel
disease and a significant proportion (32%) requiring insulin therapy [53]. The study results
showed that there was a reduction in primary endpoint all cause death, non-fatal MI and stroke in
the CABG group, with an ARR of 7.9% (26.6% in the PCI group and 18.7% in the CABG group,
p=0.005) and a Number Needed to Treat (NNT) of 12.5 [Figure 2] [53]. There was also a
reduction in all-cause mortality which was 16.3% in the PCI arm and 10.9% in the CABG arm
with an ARR = 5.4% and NNT of 19 [Figure 2] [53]. This was at the cost of an increase in stroke,
as might be expected in the CABG arm of 2.8% Number Needed to Harm (NNH) of 36 [53].
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Figure 2. Kaplan-Meier Curves for composite primary outcome (all cause death, non-fatal myocardial infarction or
stroke) and all cause death in a comparison between PCI with DES compared with CABG for multivessel disease in
diabetic patients. Reproduced with permission from Farkough ME et al. NEJM 2012. DOI 10.1056/NEJMoa1211585.
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6.3. Degree of ischemia and revascularization: Is the effect independent of symptoms?
Although there is paucity of randomized data addressing the question of how the degree of
functional ischemia relates to the benefit of revascularization, there is observational data that
suggests a strong relationship [54, 55]. Adjusted risk models have suggested that patients with
less than a 10-12.5% threshold of ischemia as demonstrated by stress myocardial perfusion
imaging, the survival profile of those treated with medical therapy were similar or even
perhaps slightly better than those who are treated with revascularization [54]. However above
the threshold of 10-12.5% of ischemia, there was a graded incremental survival benefit of
revascularization over medical therapy, with a risk adjusted relative risk reduction of 50%
[Figure 3] [54].
Figure 3. Log hazard ratio for revascularization (Revasc) versus medical therapy (Medical Rx) as a function of % myo‐
cardium ischemia based on final cox proportional hazards model. Model, P< 0.0001; interaction, P=0.0305 (Repro‐
duced with permission from Hachamovitch et al. Circulation 2003. 107: 2900-2906).
This data was further corroborated by another observational study demonstrating a similar
effect in a group of asymptomatic diabetic patients [55]. This study found a 14% survival
benefit in patients with a high-risk myocardial perfusion scan treated with CABG over medical
therapy [55]. Patients treated with PCI in the high-risk scan group did not achieve a survival
benefit over medical therapy [55]. This may be due to the fact that, this treatment group
consisted of only 10.7% three vessel disease and no patients with left main disease whereas in
the CABG group, this was 52.1% and 20.8% respectively [55]. The other caveat to this data is
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the low overall use of optimal medical therapy, which may overestimate the effect size of
revascularization in some anatomic subgroups. The use of ASA, ACEi’s and BB’s were all 40%
or less with no mention of statin therapy [55].
In summary, patients with moderate to high-risk scans by myocardial perfusion have signif‐
icant survival advantage if treated with revascularization over medical therapy alone even in
the absence of symptoms [54, 55]. This benefit has more convincingly been demonstrated in
patients undergoing CABG [54, 55]. Although the current standard and use of optimal medical
therapy has improved over time, this effect is likely still significant. This survival benefit in
the high-risk scans has not been clearly demonstrated in patients treated with PCI in stable
coronary disease. Recently, the COURAGE trial involving over 2000 patients, which compared
optimal medical therapy plus PCI with optimal medical therapy alone in stable CAD included
a high prevalence of MVD (over two thirds) associated with the same proportion of multiple
reversible defects by myocardial perfusion imaging [56]. This study showed, after exclusion
of patients with high-risk anatomy (LM) and markedly positive exercise stress testing (sub‐
stantial ST depression or hypotensive response in stage I Bruce protocol), no significant
difference in all cause death and non-fatal myocardial infarction between the medical therapy
and PCI groups [56].
6.4. Impact of complexity of disease
6.4.1. The synergy between PCI with taxus and cardiac surgery (SYNTAX) score
The SYNTAX score was designed as a comprehensive tool to classify the anatomic complexity
and functional severity of a patients’ coronary anatomy [57]. It is in fact an amalgamation of
five different scoring/classification systems which can be distilled into three basic guiding
principles: the first which describes the segments of the coronary artery tree; the second which
describes the relative importance of the lesion based on the location and vascular territory to
which the lesion impedes flow; the third which describes the complexity of the lesion [Table 1].
6.4.2. The SYNTAX trial
As techniques and technology for percutaneous coronary intervention have evolved, there has
been an increasing number of patients with multivessel disease treated with percutaneous
intervention [58]. The SYNTAX trial has evaluated the PCI versus CABG in patients with highly
complex disease in the contemporary context of paclitaxel drug eluting stenting [51]. At 12
months there was a significantly lower incidence of the primary outcome of major cardiac and
cerebrovascular events (MACCE) (ie. all cause death, stroke myocardial infarction or repeat
revascularization) CABG group compared than the PCI group with an ARR of 5.4% or NNT
19 [51]. This was largely driven by an increase need for repeat revascularization as the rates of
all cause death, MI or stroke was similar between the two groups [51]. In the initial subgroup analysis
at 12 months, while there was a trend towards lower MACCE in the CABG group compared to
the PCI group as the SYNTAX scores increased, a significantly lower rate of the primary outcome
could only be demonstrated at the highest SYNTAX scores (>33) [Figure 4] [51].
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The 3-year follow-up for this study more definitively demonstrated that PCI and CABG tended
to have similar cardiovascular outcomes in patients with lower complexity while at higher
levels of anatomical complexity, patients that underwent CABG faired better [Figure 5] [59].
At three-year follow-up, patients with 3VD in the CABG group versus the PCI group with
intermediate complexity (SYNTAX Score 23-32) had overall decrease in MI with an ARR of
5.8% and those with the highest complexity (SYNTAX Score >33) had a decrease in all cause
mortality (ARR of 6.6%) and a decrease in MI (ARR of 5.3%) [51, 59]. This was also reflected
in an overall lower all-cause death in the 3VD patients treated with CABG versus PCI with an
ARR of 3.8% (p=0.02) and a lower rate of cardiac death in those treated with CABG versus PCI
ARR 3.3% (p=0.01) [59]. Interestingly, there was no significant difference for all-cause death or
cardiac death between the CABG group versus the PCI group among patients with LM disease
[59]. In contrast to those with 3VD, there were only significantly lower MACCE rates among
patients with LM disease treated with CABG compared with PCI at the highest SYNTAX scores
(>33) [59]. Although it is difficult to make precise conclusions regarding the subgroup analyses,
the overall trends are certainly compelling.
The recent SYNTAX trial has heralded a new era in revascularization. The recent European
Guidelines have responded to the findings by giving a IIa recommendation (level B evi‐
dence) to PCI for revascularization in 3VD with low angiographic complexity (SYNTAX score
≤22) while giving a class III recommendation (level A evidence) for revascularization of such
patients moderate to high angiographic complexity (SYNTAX score >22) [26]. The most recent
ACC/AHA PCI guidelines state that in patients with 3VD with or without proximal LAD,
revascularization with PCI for the purposes of prognosis is of uncertain benefit (IIb recom‐
mendation, level B evidence) [14]. In these populations, CABG is still given Class I recom‐
mendation (level B evidence) [Table 2 and 3] [14, 26].
Principle Description
Definition and segmentation of
the coronary artery tree
1. The coronary tree can be divided into 16 major segments
Functional significance 2. Functional importance of the particular epicardial vessel is weighted according to
the percentage of the left ventricle to which it supplies. For example the left main
supplies 5 times the vascular territory compared to that of a dominant RCA; hence the
LM will be given a score of 5 whereas the RCA will be given a score of 1.
Lesion Complexity 3. The complexity of the lesion itself can be described in terms of
a. Degree of involvement of side branches, anatomic configuration of lesions
b. Presence or absence of a total occlusions and presence of collaterals
c. Lesion length
d. Tortuousity of vessel
e. Presence or absence of heavy calcification
f. Presence or absence of Thrombus
g. Presence or absence of diffuse disease
Table 1. Principles underlying the development of the SYNTAX score
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Figure 4. 12-month Subgroup analysis of the rates of (all cause death, stroke, myocardial infarction and repeat revas‐
cularization) between those treated by CABG versus PCI stratified by SYNTAX score. A significant difference in the
overall rates was not significantly different at low (<22) and intermediate (23-32) SYNTAX scores. At the highest SYN‐
TAX score (>33), there was a significantly lower rate of major cardiac and cerebrovascular events. Reproduced with
permission from Serruys PW et al. NEJM 2009. 360;10: 961-972.
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Figure 5. 3-year subgroup analysis of the rates of MACCE (all cause death, stroke, myocardial infarction and repeat
revascularization) between those treated by CABG (blue line) versus PCI (yellow line) stratified by SYNTAX score: Low
SYNTAX Score (0-22), Intermediate SYNTAX Score (23-32), High SYNTAX Score (>33). Results are provided for overall
group (A-C), 3VD patients (D-F) and LM patients (G–I). Reproduced with permission from Kappetein et al. European
Heart Journal 2011. 32: 2125-2134.
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Table 2. ESC Guidelines on revascularization for complex coronary disease. Indications for CABG and PCI are tabulated
for stable patients with low predicted surgical mortality and lesions suitable for either modes of revascularization.
CABG= coronary artery bypass grafting; CAD= coronary artery disease; LAD = left anterior descending; PCI=
percutaneous coronary intervention; VD= vessel disease. Reproduced with permission from Wijns W et al. European
Heart Journal 2010. 31: 2501-2555.
Artery Bypass332
Table 3. ACC Guidelines on revascularization for complex coronary disease to improve survival. Indications for CABG
and PCI are tabulated. CABG = coronary artery bypass grafting; COPD= chronic obstructive pulmonary disease; EF=
ejection fraction; LAD=left anterior descending artery; LIMA= left internal mammary artery; LV =left ventricular; N/A=
not applicable; PCI = percutaneous coronary intervention; SIHD = stable ischemic heart disease; STEMI= ST-elevation
myocardial infarction; STS= Society of Thoracic Surgeons; SYNTAX = Synergy between percutaneous coronary
intervention with TAXUS and Cardiac Surgery; TIMI= Thrombolysis in myocardial infarction; UA/NSTEMI =unstable
angina/ non-ST elevation myocardial infarction; UPLM= unprotected left main disease; VT=ventricular tachycardia.
Reproduced with permission from Levine GN et al. Circulation 2011. 124: e574-e651.
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For those with unprotected left main disease (UPLM), both the ACC and ESC guidelines still
give a Class I recommendation for CABG in all cases (Classified as Grade A evidence for
ESC and Grade B evidence for ACC) [14, 26]. They have both also given a IIa recommendation
for PCI in Stable Ischemic Heart Disease (SIHD) in UPLM when the SYNTAX is 22 or less
(eg isolated ostial or main trunk LM) and IIb recommendation for PCI for low or inter‐
mediate SYNTAX score (<33) (Level B evidence) [14, 26]
It is recognized however, that some populations are not expected to derive prognostic benefit
from revascularization. In such groups for the purposes of alleviating symptoms refractory to
optimal medical therapy, CABG and PCI have equivalent Class I recommendation (level A
evidence) unless SYNTAX is >22 in which case CABG is still favored (Class IIa recommen‐
dation, level B evidence) [14].
7. PCI versus CABG in acute coronary syndromes versus stable ischemic
coronary artery disease
7.1. Non-ST-elevation acute coronary syndromes (NSTEACS)
Although there are limited studies designed to address this specific question, it is generally
accepted that the same considerations that are used to decide between PCI and CABG in stable
ischemic coronary artery disease would be applied when faced with an NSTEACS (Class I
recommendation, Level B evidence) [14]. Comparisons between PCI and CABG have typically
included a mixture of patients with stable and unstable symptoms [45]. The ERACI II study
contained the highest proportion of patients with unstable symptoms constituting 92% of the
randomized patients whereas MASS II included the least with 0% having unstable symptoms
[60, 61]. However in a large meta-analysis including individual patient data from 10 large
randomized studies (n=7812) did not reveal any significant interaction between the presence
or absence of unstable symptoms and mode of revascularization (PCI vs CABG) with respect
to mortality outcomes over a 5 year period [45].
The optimal approach to PCI in the setting of a NSTEACS and MVD is still somewhat uncertain.
There are currently no randomized trials in the literature comparing the multivessel PCI to
culprit only PCI in NSTEACS [62].
7.2. ST -elevation acute coronary syndromes (STEACS)
Primary PCI remains the main modality of revascularization in STEACS (Class I recommenda‐
tion, Level A evidence). It is common to encounter MVD during the index angiogram for STEACS
having an estimated incidence of up to 40-50 percent [62]. Current evidence supports primary
PCI of the culprit vessel only, in the absence of hemodynamic instability, as the optimal
approach [14, 62, 63]. Multivessel PCI in this setting has been associated with a higher mortality and
is not recommended (Class III recommendation, Level B evidence) [14, 62, 63]. The approach to
residual coronary disease has been a subject of controversy and the decisions are likely made
clinically on an individual basis.
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7.3 Cardiogenic shock
The optimal mode of revascularization in patients with multivessel disease and cardiogenic
shock is still under debate due to lack of supporting evidence for or against either PCI or CABG.
It has been previously shown in the Should We Emergently Revascularize Occluded Arteries
for Cardiogenic Shock (SHOCK) Trial that urgent revascularization with PCI or CABG for
cardiogenic shock in the setting of STEACS has mortality benefit with an ARR of 13 percent or
NNT of 8 at 6 months compared with medical management [64]. This difference continued
out to one year and remained stable at long-term follow up [Figure 6] [65, 66]. In the revascu‐
larization group, 64 percent were treated with angioplasty whereas 36 percent were treated
with CABG [64]. Interestingly, because the mode of revascularization was at the discretion of
the treating physicians, patients treated with CABG compared with those that received PCI
tended to more often have LM disease and 3VD [64]. Nevertheless, there was no significant
difference between patients treated with PCI versus CABG at either 30 days or at 1 year [64].
Certainly the advantage of PCI for revascularization over CABG would be a reduced time
required to achieve revascularization; the time of randomization to first revascularization
attempt was 0.9 hour for PCI and 2.7 hours for CABG [64].
Figure 6. Kaplan-Meier Survival Curves For Early Revascularization Versus Initial Medical Stabilization in Long Term
Follow-Up. ERV= Early Revascularization; IMS =Initial Medical Stabilization. Reproduced with permission from Hoch‐
man JS. et al. JAMA 2006. 295;21: 2511-2515.
There is a lack of randomized data regarding the optimal mode of revascularization in
cardiogenic shock for acute coronary syndromes [67]. Currently, both the ACC and ESC
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guidelines recommend that PCI (or emergency CABG) should be performed on patients who
candidates for revascularization in the setting of STEMI and severe heart failure or cardiogenic
shock (Class I recommendation, Level B evidence) [14, 26]. Although the data upon which this
recommendation is based does not show a preferential benefit to either mode of revasculari‐
zation, both guidelines favor PCI as the primary mode of revascularization in cardiogenic
shock [14, 26]. The ACC guidelines do recognize however, that “select patients with severe
3VD or LM disease can benefit from emergency CABG” [14].
8. Treatment of hemodynamically significant disease
Currently, the ACC/ AHA defines a significant stenosis as “Greater than or equal to 70%
luminal diameter narrowing, by visual assessment, of an epicardial stenosis measured in the
“worst view” angiographic projection [68].” The exception is the left main artery in which a
significant stenosis is defined as “ greater or equal to 50% luminal diameter narrowing [68].”
A challenge in the interpretation of the data surrounding comparisons of PCI versus CABG
the variability in definitions of “significant disease.” Interestingly, many of the landmark trials
comparing PCI versus CABG actually defined a significant stenosis as greater or equal to 50%
[27, 45, 51].
Even in the presence of a significant stenosis, myocardial blood flow can be maintained by
compensatory mechanisms at rest [69]. Consequently, hemodynamically significant disease
has been defined by those lesions,  which produce a  reduction in coronary flow reserve
under  conditions  of  maximal  hyperemia [69,  70].  Reduction of  coronary flow reserve is
generally observed in lesions with as little as 50 percent stenosis but progressively wor‐
sens with the degree of narrowing [70]. There are two implications of this clinically. First,
there is a significant interobserver and intraobserver variability in the degree of angiograph‐
ic stenosis [69]. Second, the hemodynamic significance of a given lesion is dependent on
the severity of the stenosis, the length of the lesion as well as the presence of collateral blood
flow [71].
Aims to quantify the functional significance of coronary stenosis lead to the development
of the concept Fractional Flow Reserve (FFR) [72]. FFR is a hemodynamic construct defined
as the maximal blood flow distal to a stenosis compared with the maximal blood flow in
the  same  vessel,  hypothetically  in  the  absence  of  any  stenosis,  conditions  of  maximal
hyperemia [72]. Flow can be characterized by the following equation: Pressure (P) = Flow
(Q) * Resistance (R) [72]. For a given lesion, the FFR is the maximal flow for the stenotic
vessel (Qs)/ maximal flow if the vessel were normal (Qn). Since, under maximal hypere‐
mia, the resistance becomes a constant, Q is only dependent on the pressure and fraction‐
al flow reserve can be defined by a ratio of aortic pressure (Pa)/ pressure distal to the lesion
(Pd) [Figure 7] [72].  FFR allows for the functional assessment of ischemia at the time of
coronary angiogram [72].
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Figure 7. A schematic depiction of the concept of fractional flow reserve. On the right is the graphical correlation be‐
tween Flow Q and perfusion pressure P under conditions of maximal hyperemia. The maximal blood flow in the sten‐
otic vessel QS (Red Lines) is directly proportional to the perfusion pressure distal to the lesion. The maximal blood flow
in the same vessel hypothetically without the stenosis QN (Blue Lines) is proportional to the perfusion pressure proxi‐
mal to the stenosis Pa which is the same as aortic pressure. QS/QN is therefore equal to Pd/Pa. Reproduced with per‐
mission from Pijls NHJ et al. JACC 2012. 59: 1045-57.
The use of FFR will be come increasingly more relevant in the assessment of patients with
multivessel disease. The Fractional Flow Reserve Versus Angiography for Multivessel
Evaluation (FAME) was a study randomizing 1005 patients to either angiographically guided
PCI or PCI guided by fractional flow reserve in patients with multivessel disease of at least
moderate severity (greater or equal to 50%) [73]. Patients in the angiographic group were
revascularized if PCI was indicated based on visual assessment of angiographic data and
clinical data; patients in the FFR group only had PCI if the FFR was < 0.80 [73]. The combined
outcome of death, myocardial infarction and repeat revascularization was significantly less in
those treated with FFR guided PCI (18.3%) than the angiographically guided PCI (13.2%)
[Figure 8] [73]. Death and myocardial infarction, although not a pre-specified outcome, was
also significantly less in the FFR group (11.1%) versus the angiographic group (7.3%) [73]. This
difference persisted to the two-year follow-up [74].
Although FFR is early in its development, certainly it has the potential to play a role in
classifying the severity of disease for decision-making in MVD. Consider a patient with 3VD
with a 50 percent lesion at the proximal LAD. If the proximal LAD lesion is FFR is greater than
0.80, this patient may in fact be classified as two vessel disease with no hemodynamic in‐
volvement of the proximal LAD and hence should receive PCI. While there is limited research
exploring the use of FFR in determining the mode of revascularization, this is certainly an area
worthy of further study. Currently the ACC advocates the use of FFR guiding revascularization
decisions in stable ischemic heart disease with moderate lesions with 50-70% stenosis (IIa
recommendation, level A evidence) [14].
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9. Current trends in PCI versus CABG in North America
The practice patterns regarding PCI and CABG have changed dramatically within the last
10-15 years. In the earlier part of this last decade, rates of PCI have been observed to be on the
rise both in the United States and in Canada despite relatively more static rates of CABG over
that same period [75, 76]. Furthermore, although there is some signal that the trend in PCI rates
have begun to plateau or reverse in the latter part of this decade both in the United states and
in Canada, there is still a consistent increase in the overall PCI: CABG ratio [77, 78].
These recent trends have been an area of increasing research interest, as it seems paradoxical
in the context of relatively consistent practice guidelines from the ACC and the ESC supporting
the use of CABG as the first line mode of revascularization in prognostically important stable
Figure 8. Kaplan-Meier Survival Curves according to study group PCI guided by angiography alone versus PCI guided
by FFR in addition to angiography. FFR=fractional flow reserve, PCI=percutaneous coronary intervention. Reproduced
with permission from Tonino PAL et al. Fractional flow reserve versus angiography or guiding percutanous coronary
intervention. NEJM 2009. 360(3):213-224.
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ischemic coronary artery disease [Figure 9] [14, 26]. In fact, recent data has demonstrated a rise
in PCI with DES in patients with Class I recommendation for surgery [25].
Significant variability in PCI: CABG ratio between provinces/states, between hospitals and even
between individual interventionalists suggests that the trends in revascularization practices are
not  entirely  explained  by  changes  in  population  or  advancements  in  revascularization
techniques [76-80]. In Ontario, Canada, PCI to CABG ratios vary considerably between hospitals
from 1.3 to 6.1 [81]. In multivessel disease, this ratio ranges from 0.24 to 5.0 [figure 9] [82]. The
physician performing the diagnostic catheterization (interventional cardiologist versus non-
interventional cardiologist), the coronary anatomy (LM, 3VD, 2VD), and the treating hospital
were the three strongest determinants of the ultimate therapeutic strategy [58].
Two possible hypotheses for the presence of such dramatic variability in the management of
multi-vessel disease include misinterpretation of the evidence and misclassification of disease
complexity at the time of diagnostic angiogram. There are complex interacting variables upon
which the final therapeutic decision is based, including: (1) complexity of coronary anatomy,
(2) presence or absence of prognostically important factors favoring surgery, (3) degree of
active functional ischemia, (4) complex co-morbid state of patient, (5) patient preferences and
social factors, (6) local resources and expertise. All of these factors may affect the patient’s
suitability for CABG and likelihood to benefit prognostically from surgical revascularization.
Application of the large body of evidence in this variable clinical milieu is a complex process.
The management algorithm is further complicated when considering the patient’s role in the
decision-making process and the steps required to ensure truly “informed” patient consent.
Figure 9. Variation in Revascularization for Multivessel Disease Across 17 Cardiac Centers in Ontario. Reproduced with
permission from Schwalm JD et al. SYNTAX Score and Real World Revascularization Patterns. Canadian Cardiovascular
Congress 2011 Vancouver, BC. Abstract Presentation.
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10. Angioplasty versus bypass surgery: An evolving complex decision
analysis
10.1. Establishing a general approach
Decisions regarding revascularization are complex and have been founded on decades of
evidence. This body of evidence has evolved in parallel with advances in treatment but also a
patient population with increasing medical complexity. Therefore, a contemporary approach
to MVD and revascularization must be founded on an understanding of the wide spectrum of
disease severity, advances in medical/surgical therapy, diversity in patient populations,
patient preference and social circumstances. Optimal treatment strategies must apply the most
current evidence in an appropriate clinical context. Furthermore, guiding principles of
management with a multidisciplinary ‘Heart Team’ approach should be the cornerstone of
state of the art treatment of multivessel coronary artery disease as supported by recent
revascularization guidelines [14]. The basic approach should address a number of basic clinical
questions which address the (1) therapeutic goals of the case, (2) the presence or absence of
clinical evidence to support revascularization, (3) the presence/absence of prognostic factors
that may make surgical revascularization more favorable, (4) whether the anatomy favor PCI
or CABG, (5) is the patient a good surgical candidate should prognostic disease be present, (6)
does the patient have any particular preferences and (7) are there ambiguities that would
benefit from further discussion by a Heart Team [Table 4].
Fundamental Question
Therapeutic Goals: ● Can we improve survival?
● Can we improve symptoms?
● Can we improve both?
Clinical Evidence to support revascularization ● Severity of disease
● Severity of Symptoms
● Degree of Ischemia
● Degree of Medical Optimization
Prognostic Factors that may make surgical
revascularization more favorable?
LM, 3VD, or 2VD with proximal LAD with
● DM
● LV dysfunction
● High burden of ischemia ("/≥12.5 percent)
Does anatomy favor one mode of revascularization
versus the other?
● Surgical targets
● Diffuseness of disease
● Complexity
Is the patient a good surgical candidate? Consider:
● Age
● Co-morbidities
● Anatomy
Patient Preference and Social Factors Discussed off the catheterization table
Ambiguities in Case? Would this benefit from discussion with the Heart Team?
Table 4. Key clinical questions forming the basis of the therapeutic decision for management of multivessel coronary
artery disease.
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The fundamental basis of our decisions rest on what therapeutic goals can be achieved:
improvement of survival, improvement of symptoms or both. It is important to make this distinction
because although the goal would naturally to improve on both; consider the following two
clinical scenarios:
• In a 50 year-old asymptomatic patient with 70% distal LM, CABG is the treatment of choice
regardless of his symptom profile because of known survival benefit with surgical revas‐
cularization (Class I, Level A evidence)[14]
• In a 90 year-old, medically optimized, CCS class III patient who has 3VD and normal ejection
fraction, his age may undermine any treatment for the purposes of prognosis, hence PCI
may be favored if technically feasible as the overriding goal is for relief of symptoms. (Class
I, Level A evidence)[14]
If the intent is to improve survival, there is good evidence that supports revascularization in
certain patient populations: significant left main (>50%) or 3VD, 2VD with proximal LAD with
diabetes LV dysfunction and/or high burden of functional ischemia).
If the intent is primarily to improve symptoms (eg. The clinical profile undermines the prognostic
benefit of surgical revascularization), there is good evidence that revascularization with PCI is of
benefit in those who are symptomatic despite optimal medical therapy if technically feasible.
But with advances in medical therapy, it is reasonable to maximize medical treatment before
considering revascularization [56].
10.2. The decision algorithm
Based on existing evidence and guidelines, we have developed an algorithm that may help
guide decision-making in the management of MVD [Figure10]. There are a number of factors
that support surgical revascularization in SIHD for improving survival over medical therapy
or PCI, namely: 1) LM disease, 3VD and likely some subsets of 2VD with proximal LAD; 2)
MVD in the presence of mild to moderate LV dysfunction (35-49%) 3) MVD in the presence of
diabetes 4) coronary anatomy of intermediate to high level of complexity (SYNTAX >22) and
5) high burden of ischemia (>12.5%). If these are present, then surgery should be considered
first unless patient preference dictates otherwise (Class I recommendation, Level B Evidence).
If the patient does have prognostic disease, then considering the overall coronary anatomy,
patients clinical profile and co-morbidities must be considered to ultimately guide the
appropriate therapeutic decision. These factors may alter the likelihood of benefit from
revascularization and also affect the patients’ potential eligibility CABG and PCI.
If the patient does not appear to have prognostic disease and is not likely to prognostically
benefit from revascularization, then the primary goal of treatment would be symptoms. The
first goal of alleviating symptoms is medical optimization. If the patient has unacceptable
symptoms despite optimal medical therapy, then revascularization (PCI or CABG) would be
indicated (Class I recommendation, Level A Evidence).
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11. The Role of the heart team in the future of multivessel disease
The management of CAD with the advances in revascularization techniques and medical
therapy, changing patient population and constantly expanding body of knowledge is
becoming increasingly more complex. Such complexity would intuitively benefit from a broad
spectrum of expertise. There is currently increasing interest in the area of multidisciplinary
decision-making and both ACC and ESC have recommended that a Heart Team approach be
implemented in the management of UPLM disease or complex CAD (Class I recommendation,
Level C Evidence) [14, 26]. It is envisioned that with the joint involvement of the interventional
cardiologist, the cardiac surgeon and a non-invasive cardiologist, there will be a more
balanced, consistent management of these complex cases. From the patient’s perspective, this
approach would conceivably allow them to be more informed and involved in the ultimate
Figure 10. Suggested approach for decision making in multivessel coronary artery disease. CAD= coronary artery dis‐
ease; CABG= coronary artery bypass grafting; LAD= left anterior descending artery; LM = left main disease; LV= Left
Ventricular; OMT= optimal medical therapy; PCI= percutaneous coronary intervention; SCD= sudden cardiac death;
SYNTAX = The Synergy between PCI with Taxus and Cardiac Surgery; T2DM= Type 2 Diabetes Mellitis; UA/NSTEMi =
unstable angina/Non ST elevation myocardial infarction; VT= ventricular tachycardia; 3VD = Three vessel disease; 2VD
= two vessel disease.
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treatment decision. There is currently limited data on the true impact of the Heart Team and
this is certainly an area of worthy future research.
12. The future of research in complex coronary artery disease
The approach to the management of complex CAD will continue to change with exponential
growth of knowledge in this area. The majority of clinical trials involving CABG and PCI were
largely based on complete revascularization of lesions greater than 50 percent [45]. Use of FFR
has shown that PCI with DES of moderately severe lesions (50-70 percent) guided by angiog‐
raphy alone compared with PCI of lesions guided by both angiography and hemodynamic
significance (FFR< 0.80) may actually confer a higher rate of death and MI [73]. Given our
knowledge of this finding, the SYNTAX trial (where the threshold for revascularization was
also a stenosis of 50 percent or greater) may conceivably have different results if FFR was used
to guide therapy. Furthermore, investigations with the new second-generation DES, a now
better understanding of how to utilize FFR and definition of the impact of coronary complexity
may serve as a guide to better define the populations that may benefit from PCI versus CABG.
The other area requiring more research is in the arena of collaboration for decision-making in
multivessel disease. The Heart Team, although a promising concept would benefit from formal
validation. We also need to better define what type of institutions and what type of cases would
most benefit from formal evaluation with a Heart Team approach. Furthermore as these
decisions become more complex, we will also need to find better methods/mechanisms of
informed balanced patient involvement in the final management decision.
Complex CAD remains a challenging area both from the scientific and the clinical point of
view. The goal should be to build on the research foundations in the management of MVD
CAD thus far and continue to improve our understanding of how to better manage and care
for patients with complex CAD.
Abbreviations
ACC American College of Cardiology
ACEi Angiotensin Converting Enzyme inhibitor
ARB Angiotensin Receptor Blocker
AHA American Heart Association
ARR Absolute risk reduction
ASA Aspirin
BB Beta Blocker
BMS Bare metal stent
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CABG Coronary artery bypass grafting
CAD Coronary artery disease
CI 95% Confidence interval
COPD Chronic obstructive pulmonary disease
DAPT Dual antiplatelet therapy
DES Drug eluting stent
ESC European Society of Cardiology
HMG-CoA 3-hydroxyl-3-methyl-glutaryl-coenzyme A
LAD Left anterior descending artery
LIMA Left internal mammary artery
LM Left main
MID CAB minimally invasive direct coronary artery bypass
NNH Number Needed to Harm
NNT Number Needed to Treat
NSTEACS Non ST elevation acute coronary syndrome
NSTEMI Non ST elevation myocardial infarction
PCI Percutaneous coronary intervention
POBA Plain old balloon angioplasty
RRR Relative Risk Reduction
SCD Sudden cardiac death
SIHD Stable ischemic heart disease
STEACS ST elevation acute coronary syndrome
STEMI ST elevation myocardial infarction
SYNTAX Synergy between PCI with Taxus and Cardiac Surgery
UA Unstable angina
UPLM Unprotected left main disease
VT Ventricular tachycardia
3VD Three vessel disease
2VD Two vessel disease
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